Public Profile

Epigenomics AG

Epigenomics AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative molecular diagnostics for cancer detection. Founded in 1998, the company has established itself as a leader in the field of epigenetics, particularly with its flagship product, Epi proColon, which is designed for non-invasive colorectal cancer screening. With a strong presence in Europe and North America, Epigenomics AG is committed to advancing personalised medicine through its unique biomarker-based technologies. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. By leveraging cutting-edge research and development, Epigenomics AG continues to drive advancements in cancer diagnostics, making a meaningful impact on patient care and outcomes.

DitchCarbon Score

How does Epigenomics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

15

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Epigenomics AG's score of 15 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

44%

Let us know if this data was useful to you

Epigenomics AG's reported carbon emissions

Epigenomics AG, headquartered in Germany, currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions or any established reduction targets. In the absence of concrete emissions data, it is important to note that the company may still be engaged in climate commitments or initiatives typical within the biotechnology sector. However, without specific information on their climate pledges or reduction strategies, it is challenging to provide a detailed overview of their environmental impact or sustainability efforts. As the industry increasingly focuses on reducing carbon footprints and enhancing sustainability, it is likely that Epigenomics AG will align with these trends in the future.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Epigenomics AG's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Epigenomics AG is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Epigenomics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Exact Sciences

US
Research and development services (73)
Updated 20 days ago

Guardant Health

US
Research and development services (73)
Updated 9 days ago

GRAIL, Inc.

US
Health and social work services (85)
Updated 20 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers